

## RELEVANT EVENT

Grifols (the “**Company**”) informs that Standard & Poor’s Rating Services has upgraded to BB Grifols long-term corporate credit rating, to BB+ its Senior Secured Debt and to B+ the Unsecured Debt.

Standard & Poor’s believe that Grifols will continue to perform strongly; this is supported, in their opinion, by growing demand worldwide for plasma derivative products and further synergies from the acquisition of Talecris Biotherapeutics Inc.

According to Standard & Poor’s, this should lead to a reduction of the adjusted Company’s leverage to close to 4 times by the end of 2012.

The stable outlook reflects Standard & Poor’s opinion that Grifols will continue its strong performance leading to a reduction in its debt leverage to sustainably below 4x in 2013 and thereafter.

In Barcelona, on this 1<sup>st</sup> August 2012

---

Raimon Grifols Roura  
Secretary to the Board of Directors